Healius (ASX:HLS) Valuation Rank


ASX:HLS Healius Ltd ASX:HLS
53 GF Score
Price A$0.37
GF Value A$1.01
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Healius Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Healius Valuation Rank Related Terms

ASX:HLS
53GF Score
Healius Ltd ASX:HLS
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Healius (ASX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, Healius stock appears to be undervalued. The current stock price of A$0.37 is trading 63.9% below its estimated GF Value™ of A$1.01. GuruFocus considers Healius to be Possible Value Trap.

Key valuation signals for ASX:HLS:

  • Valuation Rank:
  • GF Value™: A$1.01 vs. price of A$0.37 (63.9% below fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healius Business Description

Other Exchanges PGZ:Germany
Address 161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
53GF Score

Get the complete analysis for ASX:HLS

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.37
Price
A$1.01
GF Value